HyperHEP B®

Recommendations on post-exposure prophylaxis are based on available efficacy data and on the likelihood of future HBV exposure for the person requiring treatment.? In all exposures, a regimen combining Hepatitis B Immune Globulin (Human) with hepatitis B Immune vaccine will provide both short-and long-term protection, will be less costly than the two-dose Hepatitis B Immune Globulin (Human) treatment alone, and is the treatment of choice. HyperHEP B®S/D is indicated for post-exposure prophylaxis in the following situations when the conditions listed in the PI are met:

- Acute Exposure to Blood Containing HBsAg
- Sexual Exposure to an HBsAg-positive Person
- Household Exposure to Persons with Acute HBV Infection

For indications, dosing and other information, please refer to the prescribing information.

HyperHEP B® ‐ Grifols

Size:
0.5 mL PFS
NDC #:
13533-0636-03
Download:
PI
Size:
1 mL PFS
NDC #:
13533-0636-02
Download:
PI
Size:
5 mL vial
NDC #:
13533-0636-05
Download:
PI